Asceneuron will develop effective therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in drug discovery for neurodegenerative diseases. Current treatments for Alzheimer’s disease provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines.